Hilde Almåsbak

553 total citations
10 papers, 450 citations indexed

About

Hilde Almåsbak is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Hilde Almåsbak has authored 10 papers receiving a total of 450 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Immunology. Recurrent topics in Hilde Almåsbak's work include CAR-T cell therapy research (8 papers), Virus-based gene therapy research (2 papers) and Immunotherapy and Immune Responses (2 papers). Hilde Almåsbak is often cited by papers focused on CAR-T cell therapy research (8 papers), Virus-based gene therapy research (2 papers) and Immunotherapy and Immune Responses (2 papers). Hilde Almåsbak collaborates with scholars based in Norway, United States and Sweden. Hilde Almåsbak's co-authors include Tanja Aarvak, Mohan C. Vemuri, Gustav Gaudernack, Gunnar Kvalheim, Marit Renée Myhre, Sébastien Wälchli, Hanna Julie Hoel, Else-Marit Inderberg-Suso, Jon Amund Kyte and Even Walseng and has published in prestigious journals such as Journal of Immunological Methods, Gene Therapy and Cancer Immunology Research.

In The Last Decade

Hilde Almåsbak

9 papers receiving 442 citations

Peers

Countries citing papers authored by Hilde Almåsbak

Since Specialization

Citations

This map shows the geographic impact of Hilde Almåsbak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilde Almåsbak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilde Almåsbak more than expected).

Fields of papers citing papers by Hilde Almåsbak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hilde Almåsbak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilde Almåsbak. The network helps show where Hilde Almåsbak may publish in the future.

Co-authorship network of co-authors of Hilde Almåsbak

This figure shows the co-authorship network connecting the top 25 collaborators of Hilde Almåsbak. A scholar is included among the top collaborators of Hilde Almåsbak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilde Almåsbak. Hilde Almåsbak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Engineering mRNA CAR-T Cells for Cancer Immunotherapy 2025 ·Methods in molecular biology ·Hilde Almåsbak, Mouldy Sioud, (unknown)	0
2	Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors 2018 ·Cancer Immunology Research ·Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk‐Jarzynka, Hanna Julie Hoel, Weiwen Yang, (unknown), Hilde Almåsbak, Małgorzata Bajor, Dennis Clement, (unknown), Björn Önfelt, Jodie P. Goodridge, Magdalena Winiarska, Radosław Zagożdżon, Johanna Olweus, (unknown), Karl‐Johan Malmberg	91
3	T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reducesin vivotumor growth 2017 ·OncoImmunology ·Else Marit Inderberg, Sébastien Wälchli, Marit Renée Myhre, Sissel Trachsel, Hilde Almåsbak, Gunnar Kvalheim, Gustav Gaudernack	56
4	New dynabeads™treg CD3/CD28 and animal origin-free, serum-free media for regulatory T cell activation and expansion to be used in clinical applications 2017 ·Cytotherapy ·(unknown), Hui Zhang, (unknown), (unknown), (unknown), (unknown), (unknown), Hilde Almåsbak, Angel Varela‐Rohena, Tanja Aarvak	1
5	Optimized Process for Regulatory T Cell Activation and Expansion Using Dynabeads™ Treg CD3/CD28 for Clinical Applications 2016 ·Cytotherapy ·(unknown), (unknown), (unknown), (unknown), Hans Christian D. Aass, Anne‐Marie Siebke Trøseid, Hilde Almåsbak, Tanja Aarvak	1
6	CAR T Cell Therapy: A Game Changer in Cancer Treatment 2016 ·Journal of Immunology Research ·Hilde Almåsbak, Tanja Aarvak, Mohan C. Vemuri	132
7	Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model 2015 ·Gene Therapy ·Hilde Almåsbak, Even Walseng, Alexander Kristian, Marit Renée Myhre, Else-Marit Inderberg-Suso, Ludvig A. Munthe, Jan Terje Andersen, (unknown), Gunnar Kvalheim, Gustav Gaudernack, Jon Amund Kyte	94
8	Transiently redirected T cells for adoptive transfer 2010 ·Cytotherapy ·Hilde Almåsbak, Edith Rian, Hanna Julie Hoel, Martin Pulé, Sébastien Wälchli, Gunnar Kvalheim, Gustav Gaudernack, (unknown)	58
9	Non-MHC-Dependent Redirected T Cells Against Tumor Cells 2010 ·Methods in molecular biology ·Hilde Almåsbak, (unknown), (unknown)	6
10	A single-chain-Fv-based immunofluorometric assay specific for the CEA variant NCA-2 2003 ·Journal of Immunological Methods ·Elisabeth Paus, Hilde Almåsbak, Ole P. Børmer, David J. Warren	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact